Gilead Sciences Inc at Jefferies London Healthcare Conference Transcript
Okay. Good morning. Thank you, everyone, for joining us on the morning session here on day 2 of the Jefferies Global London Healthcare Conference. I'm Mike Yee, one of the biotech analysts at Jefferies, and I'm really pleased to have with us up here on the stage, the Chief Financial Officer of Gilead Sciences, Andy Dickinson. Andy, great to have you with us.
Questions & Answers
I would love to just maybe take a step back, talk about your outlook on 2024, but really sort of summarizing how Gilead has been positioned in 2023. You just reported earnings a couple of weeks ago. A lot of people are obviously thinking about growth at Gilead, core business, pipeline and how you're positioned for 2024.
So maybe just coming away from third quarter, give us a snapshot about how you're feeling about things. And we'll get in a little more of the details.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
